Teva Pharmaceutical Industries LTD TEVA
We take great care to ensure that the data presented and summarized in this overview for TEVA PHARMACEUTICAL INDUSTRIES LTD is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TEVA
View all-
Black Rock Inc. New York, NY43.7MShares$712 Million0.01% of portfolio
-
Ion Asset Management Ltd. George Town, Grand Cayman, E938.6MShares$628 Million36.28% of portfolio
-
Phoenix Holdings Ltd. Givatayim, L334.6MShares$563 Million7.05% of portfolio
-
Migdal Insurance & Financial Holdings Ltd.29.9MShares$486 Million6.74% of portfolio
-
Clal Insurance Enterprises Holdings LTD Tel Aviv, L328.8MShares$469 Million4.57% of portfolio
-
Menora Mivtachim Holdings Ltd.28.1MShares$458 Million3.02% of portfolio
-
Slate Path Capital LP New York, NY26.9MShares$438 Million7.63% of portfolio
-
Exor Capital LLP London, X026.4MShares$430 Million16.76% of portfolio
-
Rubric Capital Management LP New York, NY17.7MShares$288 Million8.5% of portfolio
-
State Street Corp Boston, MA16.2MShares$264 Million0.01% of portfolio
Latest Institutional Activity in TEVA
Top Purchases
Top Sells
About TEVA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Insider Transactions at TEVA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 16
2024
|
Amir Weiss Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
12,635
-70.93%
|
$202,160
$16.65 P/Share
|
May 15
2024
|
Amir Weiss Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
15,500
-46.53%
|
$248,000
$16.8 P/Share
|
May 13
2024
|
Vikki L Conway |
SELL
Open market or private sale
|
Direct |
15,219
-100.0%
|
$243,504
$16.74 P/Share
|
Mar 06
2024
|
Eliyahu Sharon Kalif EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
77,550
-27.57%
|
$1,008,150
$13.52 P/Share
|
Mar 05
2024
|
Eric Drape Executive VP Global Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
77,802
+23.69%
|
-
|
Mar 05
2024
|
Eliyahu Sharon Kalif EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
73,707
+11.91%
|
-
|
Mar 05
2024
|
Richard Daniell Exec. VP, European Commercial |
SELL
Open market or private sale
|
Direct |
48,629
-22.65%
|
$632,177
$13.52 P/Share
|
Mar 05
2024
|
Richard Daniell Exec. VP, European Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
77,802
+25.14%
|
-
|
Mar 05
2024
|
Vikki L Conway |
SELL
Open market or private sale
|
Direct |
1,427
-8.57%
|
$18,551
$13.52 P/Share
|
Mar 05
2024
|
Vikki L Conway |
BUY
Exercise of conversion of derivative security
|
Direct |
4,954
+22.94%
|
-
|
Mar 05
2024
|
Mark Sabag EVP, International Markets |
SELL
Open market or private sale
|
Direct |
100,000
-20.72%
|
$1,300,000
$13.52 P/Share
|
Mar 05
2024
|
Mark Sabag EVP, International Markets |
BUY
Exercise of conversion of derivative security
|
Direct |
81,897
+8.03%
|
-
|
Mar 05
2024
|
Amir Weiss Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,564
+9.66%
|
-
|
Mar 04
2024
|
Vikki L Conway |
SELL
Open market or private sale
|
Direct |
3,532
-16.62%
|
$45,916
$13.37 P/Share
|
Mar 04
2024
|
Vikki L Conway |
BUY
Exercise of conversion of derivative security
|
Direct |
7,117
+34.13%
|
-
|
Mar 04
2024
|
Eric Drape Executive VP Global Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
33,512
+30.07%
|
-
|
Mar 04
2024
|
Richard D Francis President and CEO |
SELL
Open market or private sale
|
Direct |
31,061
-20.12%
|
$403,793
$13.34 P/Share
|
Mar 04
2024
|
Richard Daniell Exec. VP, European Commercial |
SELL
Open market or private sale
|
Direct |
95,762
-39.8%
|
$1,244,906
$13.34 P/Share
|
Mar 04
2024
|
Richard Daniell Exec. VP, European Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
33,512
+24.5%
|
-
|
Mar 04
2024
|
Eric A Hughes |
SELL
Open market or private sale
|
Direct |
8,045
-32.31%
|
$104,585
$13.34 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 1.2M shares |
---|
Open market or private sale | 811K shares |
---|